Cytotoxic agents， molecular targeted agents and immune checkpoint inhibitors consist of the fundamental model of cancer systematic treatments. Anti-tumor drugs with new mechanisms of action， including kinase inhibitors， therapeutic antibodies， nucleic acid blocks， therapeutic vaccines， gene-edited immune cells， living microrobots and digital drugs， will change this existing model. Drugs targrting nerves， polysaccharides， lipids and microflora may gradually enter clinical applications.